|
 |
TaxotereThis page contains recent news articles, when available, and an overview of Taxotere but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Worldwide sales of Taxotere®, the Sanofi-Aventis brand of the drug, exceed 3 billion USD annually. While the specific terms of the agreement remain ... Earthtimes (press release) BioVectra confirme son partenariat destiné à lancer le Docetaxel sur le marché ... - 06 Jan 2010 Docetaxel administré par injection (Taxotere®) est un traitement par chimiothérapie antimitotique cliniquement prouvé, principalement utilisé pour traiter ... TF1 BioVectra bestätigt Partnerschaft zur Vermarktung von Docetaxel in den USA - 06 Jan 2010 Docetaxel ist die Generikaversion von Taxotere®, das von BioVectra entwickelt wurde. Die Vermarktungs- und Liefervereinbarungen mit Sandoz erweitern die ... PR-Inside.com (Pressemitteilung) BioVectra conferma la partnership per commercializzare Docetaxel negli USA - 06 Jan 2010 Abbreviated New Drug Application) per il Docetaxel, la versione generica del Taxotere®, sviluppato da BioVectra, per il trattamento per via endovenosa. ... Wall Street Italia FDA says OSI drug effective against lung cancer - Dec 14, 2009 The FDA on Wednesday will ask a panel of outside experts to compare Tarceva as a maintenance therapy to Tarceva or the chemotherapy drug Taxotere as a ... The Associated Press A New Year - Jan 4, 2010 I just finished my 6th round of taxotere on Wednesday. This is the first chemo that I have gone all 6 rounds. I have a petscan scheduled in January to ... EmpowHer (blog) Big Buy: ADVENTRX's NDA and Financing News (AMEX:ANX) - Jan 4, 2010 Also in development at ADVENTRX is ANX-514 Docetaxel (Taxotere) emulsion detergent free formulation. Again an easier, softer delivery system designed to ... Small Cap Network Why piling eye drops high can make a lot of sense to Novartis - Jan 4, 2010 ...a hypertension drug, a patent it shares with Bristol-Myers Squibb, and on Taxotere, an anti-cancer drug that generated $3 billion in sales. ... Times Online Addition of Avastin® to Chemotherapy Delays Breast Cancer Progression - Dec 16, 2009 Eligible patients with HER2-negative breast cancer were randomized to Taxotere (100 mg/m2 every three weeks for up to nine cycles) plus placebo or Taxotere ... Cancer Consultants Herceptin Combinations Improve Survival, Lessen Heart Toxicity - Dec 23, 2009 Consistent with results presented previously, the latest update indicates that using Taxotere (docetaxel) can make Herceptin safer for the heart. ... Curetoday.com (press release) Combination of Herceptin® with Non-anthracycline-based Chemotherapy Appears to ... - Dec 18, 2009 Based on results from the BCIRG 006 trial, both the TCH (Taxotere® and carboplatin with Herceptin) as well as the AC-TH (doxorubicin and cyclophosphamide ... Cancer Consultants Targeted Agent Tops Chemo for Selected NSCLC - Dec 21, 2009 Treatment with the targeted agent resulted in a median PFS exceeding nine months, while the conventional, cisplatin-docetaxel (Taxotere) chemotherapy ... MedPage Today ANX, ADVENTRX Pharmaceuticals (AMEX: ANX) Reports Data from Pre-Clinical Study ... - Dec 17, 2009 ANX-514 is a novel emulsion formulation of docetaxel, a chemotherapy drug formulation of which is marketed under the brand name Taxotere. ... TransWorldNews (press release) North Carolina Cancer Center Given $2 Million Towards Cancer Research - Dec 24, 2009 Sanofi is the maker of Taxotere, a chemotherapy drug for the treatment of non-small-cell lung cancer treatment. Taxotere is also used for the treatment of ... MesotheliomaHelp.net (blog) Hybrigenics raised EUR 2.7 million in a private placement - Dec 15, 2009 ...based on a very high (87 percent) response rate of patients to the combination of standard intravenous Taxotere(R) and promising oral inecalcitol. ... PharmaLive.com (press release) SA biopharmaceutical company has new cancer drug in clinical trials - Dec 18, 2009 Azaya is taking a totally new approach by encapsulating a common agent, Taxotere, in what's called a liposome. “We've simply taken an empty cell structure ... KENS 5 TV Sanofi's Multaq Fails to Win UK Cost Agency Backing - Dec 24, 2009 ...driver for Sanofi to see it through the years when patents expire on multi-billion euro drugs like cancer treatment Taxotere and blood thinner Plavix. ... New York Times Azaya Therapeutics Gets FDA Authorization For Study - Dec 11, 2009 ...said Thursday that it has received approval for starting a Phase I cancer trial of ATI-1123, the firm's new formulation of chemotherapy drug Taxotere. ... Texas Tech Pulse (blog) Novel drug combo improves breast cancer survival - Dec 11, 2009 ..._A 736-patient study of Avastin plus Taxotere or a dummy drug as first-time treatment for cancers that had recurred or spread beyond the breast. ... The Associated Press Adventrx Pharmaceuticals Inc. (AMEX: ANX) still running strong. Gains nearly ... - Dec 28, 2009 ADVENTRX also announced that a recently completed preclinical study has affirmed the bioequivalence and comparable toxicity of ANX-514 and Taxotere® ... Small Cap Network SABCS: Trastuzumab Dosing During Chemo Vindicated - Dec 13, 2009 ...and cyclophosphamide [Cytoxan] followed by paclitaxel [Taxotere]); to the same chemotherapy with trastuzumab started concurrently with the paclitaxel, ... MedPage Today 3 Reasons to Buy Dendreon Today - Dec 18, 2009 The drug appears to be more effective than sanofi-aventis' (NYSE: SNY) Taxotere and could fetch a high price, like other cancer drugs from Genentech, ... Motley Fool Health panel recommends subsidizing 80 new drugs, but wants to drop breast ... - Dec 23, 2009 The committee also decided not to recommend subsidizing docetaxel (Taxotere) for the treatment of advanced stomach stomach cancer, a drug that prolongs ... Ha'aretz FDA Panel Rejects Earlier Use of Erlotinib - Dec 17, 2009 Another drug, docetaxel (Taxotere), is also approved to treat NSCLC in the case of chemotherapy failure. Both erlotinib and docetaxel improve median ... MedPage Today Azaya Therapeutics gets FDA approval for clinical study - Dec 10, 2009 Known as ATI-1123, Azaya's compound aims to make docetaxel — the generic name for one of the most prescribed chemotherapy drugs, Taxotere — more effective ... MSN Money Azaya Therapeutics Receives FDA Authorization To Start Phase I Cancer Trial - Dec 13, 2009 Preclinical studies have demonstrated improvement in the toxicology profile and an enhanced efficacy of ATI-1123 compared to Taxotere® in a number of tumor ... Medical News Today (press release) Adventrx Inching Closer To NDA Filing Of Emulsion Formulation Of Chemotherapy Drug - Dec 20, 2009 ...another late-stage product candidate ANX-514 (docetaxel emulsion for injection), a reformulation of the blockbuster chemotherapeutic agent, Taxotere. ... RTT News SABCS: No Need for Anthracycline with Trastuzumab - Dec 12, 2009 ...docetaxel (Taxotere) -- with the same combination with trastuzumab, and to a third arm of just docetaxel, carboplatin (Paraplatin), and trastuzumab. ... MedPage Today Brandcast Strengthens Its Digital Team - Dec 21, 2009 ...worked on this basis with Brandcast for the past three years on healthcare projects such as Zaponex, Taxotere, ecancermedicalscience and HCA Hospitals. ... Econsultancy (press release) Ichan's Adventrx Pharmaceuticals Ready To Run - Dec 23, 2009 Adventrx has yet another late-stage product candidate ANX-514 (docetaxel emulsion for injection), a reformulation of the blockbuster chemo agent, Taxotere. ... FOXBusiness Mentor Capital / QI, Cancer Vaccine Investing Update Report - Dec 23, 2009 ...the life of patients with advanced prostate cancer by a median of 4.1 months, which is one month longer than the only other treatment option, Taxotere. ... istockAnalyst.com (press release) Didėja pigesnių kompensuojamų vaistų pasirinkimas - Dec 22, 2009 Pasinaudojus lygiagretaus importo galimybėmis šios grupės ligoms gydyti į kainyną įrašyti du vaistiniai preparatai "Taxotere" 80 miligramų ir 20 miligramų ... Vakarų ekspresas Mažinamos pacientų priemokos nemažai grupei kompensuojamųjų vaistų - Dec 22, 2009 ...galimybėmis šios grupės ligoms gydyti į kainyną įrašyti du vaistiniai preparatai Taxotere 80 mg ir 20 mg koncentratas bei tirpiklis infuziniam tirpalui. ... Lietuvos rytas US-Gesundheitsexperten äußern Zweifel an Tarceva-Erweiterung - Dec 14, 2009 Ein ähnliches Urteil fällte der Rat auch über den Wirkstoff Docetaxel, den der französische Pharmakonzern Sanofi-Aventis unter dem Namen Taxotere für ... Reuters Deutschland (Pressemitteilung) FDA revê Tarceva® como tratamento de manutenção para cancro do pulmão - Dec 15, 2009 A FDA explicou que o Taxotere® (docetaxel) da sanofi-aventis eo Tarceva® conferem uma sobrevida média de três meses, em comparação com o placebo, ... POP - Portal de Oncologia Portugês Sanofi announces more positive Taxotere results - Dec 13, 2007 PARIS, Dec 13 (Reuters) - French drugmaker Sanofi-Aventis (SASY.PA) said on Thursday that results at a recent industry conference showed positive results ... Reuters More data on Sanofi-Aventis's Taxotere cancer drug confirms improved ... - Dec 15, 2006 SAN ANTONIO, CA (AFX) - The Cancer International Research Group (CIRG) and Sanofi-Aventis said the second interim efficacy and safety analysis from the ... Forbes Taxotere Cuts Breast Cancer Relapse in Study - Jun 2, 2005 A cancer treatment from French drugmaker Sanofi-Aventis (SNY Quote) improved the long-term survival of breast cancer patients and reduced the risk of ... TheStreet.com - TheStreet.com (subscription) Cell Genesys slides in premarket as GVAX trials stopped after deaths - Aug 27, 2008 Cell Genesys' GVAX immunotherapy - which was in the second of two Phase III trials known as Vital-2 - combined with cancer drug Taxotere was being compared ... MarketWatch Taxotere improves survival in head-neck cancer - Oct 24, 2007 By Gene Emery. BOSTON, Oct 24 (Reuters) - Adding the Sanofi-Aventis (SNY.N) (SASY.PA) cancer drug Taxotere to standard chemotherapy helps people with head ... Reuters Sanofi's Taxotere wins US FDA priority review for gastric cancer... - Dec 2, 2005 PARIS (AFX) - Sanofi-Aventis SA said its blockbuster cancer drug Taxotere has received a 6-month priority review by the US Food and Drug Administration for ... Forbes … -Aventis says EU committee recommends Taxotere for stomach cancer … - Mar 24, 2006 PARIS (AFX) - Sanofi-Aventis SA said a committee of the European Union's European Medicines Agency has recommended the cancer drug Taxotere for use in ... Forbes Sanofi's Taxotere under priority review in US for treatment of head,... - Jun 27, 2007 PARIS (Thomson Financial) - Sanofi-Aventis said its Taxotere drug has been accepted by the US Food and Drug Administration (FDA) for filing and assigned ... Forbes Sanofi-Aventis says phase III Taxotere study shows significant … - Dec 8, 2005 PARIS (AFX) - Sanofi-Aventis said its Taxotere cancer therapy showed 'significantly improved disease free survival' rates in breast cancer patients during a ... Forbes Sanofi-Aventis gets US approval for use of Taxotere in treating head... - Oct 1, 2007 AP. PARIS – Sanofi-Aventis SA, the world's third largest drug maker, said Monday the US Food and Drug Administration has approved the use of its cancer drug ... San Diego Union - Tribune - San Diego Union Tribune Sanofi-Aventis says Taxotere more effective than paclitaxel for... - Aug 19, 2005 LONDON (AFX) - Sanofi-Aventis said treatment with its Taxotere drug offers a significant improvement over paclitaxel in overall survival for women with ... Forbes Sanofi says Taxotere shows high survival among head, neck cancer … - Oct 25, 2007 PARIS (Thomson Financial) - French pharmaceutical company Sanofi-Aventis said two clinical trials of its Taxotere cancer drug showed significantly improved ... Forbes … Biotech to evaluate Satraplatin cancer drug in combination with... - Jul 5, 2005 ...for a phase I trial to evaluate its cancer drug Satraplatin in combination with Sanofi-Aventis' Taxotere in patients with advanced solid tumours. ... Forbes Avastin Helps Slow Breast Cancer in Study - May 31, 2008 ...a placebo plus the Sanofi-Aventis (SNY Quote) chemotherapy drug Taxotere; a low dose of Avastin plus Taxotere; or a high dose of Avastin plus Taxotere. ... TheStreet.com - TheStreet.com (subscription) Patients 'denied prostate drug' - Nov 3, 2006 Taxotere can improve the quality of life of patients in the later stages of the cancer, ... Taxotere was originally developed to treat breast cancer. ... BBC News Weekly Doses of Taxol Prolonged Lives of Breast Cancer Patients - Apr 16, 2008 The other taxane, Taxotere (docetaxel) is more potent than Taxol. ... They also compared Taxol with Taxotere (four cycles every three weeks) or Taxotere ... Washington Post Deadly problems halt breast cancer study - May 17, 2005 Docetaxel, or Taxotere, belongs to a class of cancer drugs that also includes Taxol. These drugs are derived from the yew tree and have shown promise in ... msnbc.com Sanofi's Taxotere gets positive opinion for use in head and neck... - Sep 22, 2006 PARIS (AFX) - Sanofi-Aventis said its Taxotere drug received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe for ... Forbes EU agency recommends against extended Taxotere use - Jul 25, 2008 LONDON, July 25 (Reuters) - The European Medicines Agency has recommended against extended use of Sanofi Aventis' (SASY.PA) drug Taxotere to treat HER2 ... Reuters Sanofi blockbuster found effective in other cancer - Jun 4, 2006 This is the latest form of treatment that has been studied for Taxotere, ... Taxotere is one of the top earners for Paris-based Sanofi-Aventis, ... CNN Novacea Announces Preliminary Findings From Data Analysis of Ascent- … - Jun 4, 2008 ASCENT-2 was an open-label trial that randomized patients to either combination therapy with Asentar and Taxotere or Taxotere alone. ... marketwire.com Sanofi announces positive results in Taxotere trials - Sep 4, 2007 PARIS, Sept 4 (Reuters) - Sanofi-Aventis (SASY.PA), the world's third-biggest drugmaker, said on Tuesday that latest clinical trials had revealed positive ... Reuters Euroshares open higher, Sanofi-Aventis up on Taxotere report - Aug 19, 2005 LONDON (AFX) - Shares on Europe's leading bourses moved higher in morning deals, with Sanofi-Aventis outperforming after some positive drugs research, ... Forbes Prostate cancer drug cleared for free use - Jun 28, 2006 Taxotere, which was originally developed to treat breast cancer, ... Taxotere, the brand name for docetaxel, fights cancer by blocking the mechanism that ... Daily Mail Approval for cancer patient drug - May 8, 2007 Taxotere, which will be used to treat sufferers of head, neck, ... In trials, patients taking Taxotere had a 30% lower mortality rate than those receiving ... BBC News Drug trial halted; Cell Genesys shares plummet - Aug 28, 2008 Of those, 67 had received GVAX with the chemotherapy drug Taxotere. The other 47 deaths came in a control group taking Taxotere and prednisone, ... San Francisco Chronicle FDA approves Taxotere for head and neck cancers - Oct 18, 2006 The Food and Drug Administration (FDA) today approved Taxotere (docetaxel) Injection Concentrate for use in combination with cisplatin and fluorouracil ... News-Medical.net Paris AFX market data at 10.00 am; Sanofi-Aventis up on Taxotere study - Aug 19, 2005 ...-Sanofi-Aventis, up 1.80 eur at 72.40, after reporting that a study showed its Taxotere drug had better results than Paclitaxel in treating breast cancer. ... Forbes Vitamin pill for prostate cancer - Jan 20, 2007 The phase II trial used a less than optimal taxotere regime so the survival rate may have been artificially inflated. Professor James said vitamin D was ... BBC News Roche gets UK approval for lower-priced Tarceva - Oct 6, 2008 PA) Taxotere. The draft recommendation is expected to be confirmed in final guidance to be issued next month by NICE, the body responsible for determining ... Reuters Paris shares up at midday; Sanofi outperforms on Taxotere study news - Aug 19, 2005 PARIS (AFX) - Share prices were higher at midday, with selected stocks responding to specific news as the broader market awaited direction from Wall Street, ... Forbes … of a Meta-Analysis Show Benefits of Taxotere(R) (Docetaxel)... - Jun 3, 2006 PARIS, June 3 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that a meta-analysis performed on seven clinical trials in patients with advanced ... RedOrbit Bone drug Zometa helps fight breast cancer spread - Jun 2, 2008 Taxotere treatment is more common in Europe and Asia; in the United States, ... In the study of 736 women, 44 percent of those given just Taxotere had their ... 中国日报 - 中国日报 REFILE-UPDATE 1-Cell Genesys prostate cancer drug shows promise - Apr 3, 2007 ..."The company has two independent phase 2 studies, both of which outperformed the current standard of care Taxotere," Canaccord Adams analyst Joseph ... Reuters UK Active Biotech takes ANYARA plus Taxotere into Phase I study. - Nov 8, 2005 Active Biotech AB has entered into Phase I clinical study with a combination of the drug candidate ANYARA and the anticancer agent Taxotere as a treatment ... Pay-Per-View - Dagens Industri - Factiva, from Dow Jones Taxotere(R) Receives US FDA Approval For The Treatment Of Patients … - Oct 19, 2006 Sanofi-aventis announced today that following a priority review of a supplemental new drug application (sNDA), the US Food and Drug Administration (FDA) has ... Medical News Today - Medical News Today (press release) Sanofi-Aventis Sues Apotex Over Taxotere Patents - Aug 11, 2008 By Phil Milford. Aug. 11 (Bloomberg) -- Sanofi-Aventis SA, France's largest drugmaker, sued Canada's Apotex Inc. claiming infringement of two US patents for ... Bloomberg Costly prostate cancer drug Taxotere may be subsidised - Jul 6, 2007 PROSTATE cancer sufferers should find out within the next fortnight whether an expensive treatment will be subsidised by the Federal Government. ... NEWS.com.au HEALTH CHIEFS' BAN ON PROSTATE CANCER DRUG - Nov 8, 2005 He added: "Taxotere is regarded by many doctors as the treatment of choice. ... Patients will only be able to obtain Taxotere by paying for it, ... Scottish Daily Record |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |